This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -30.77% and 1.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Stock Jumps 7.6%: Will It Continue to Soar?
by Zacks Equity Research
Owens & Minor (OMI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Are Medical Stocks Lagging Avinger (AVGR) This Year?
by Zacks Equity Research
Here is how Avinger (AVGR) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -58.82% and 2.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 2.27% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 0% and 3.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Ayr Wellness Inc. (AYRWF) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ayr Wellness Inc. (AYRWF) and Align Technology (ALGN) have performed compared to their sector so far this year.
Why Fast-paced Mover Ayr Wellness Inc. (AYRWF) Is a Great Choice for Value Investors
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, Ayr Wellness Inc. (AYRWF) Is Still a Bargain Stock
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -38.46% and 0.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -17.86% and 13.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ayr Wellness Inc. (AYRWF) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
Ayr Wellness Inc. (AYRWF) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Ayr Wellness Inc. (AYRWF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Medical Stocks Lagging Haemonetics (HAE) This Year?
by Zacks Equity Research
Here is how Haemonetics (HAE) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Ayr Wellness Inc. (AYRWF) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -5% and 3.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 13.33% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 18.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?